Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 3/20 | 0.47 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.44 |
| ▸ | WNT1 | P04628 | 2/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10153117 | 0.90 | NTRK1 (0.51) | METNTRK1DYRK1AWNT1GSK3B | |
| SCHEMBL319690 | 0.89 | MET (0.52) | METNTRK1DYRK1AWNT1GSK3B | |
| Hydrochloric Acid SCHEMBL320673 | 0.89 | NTRK1 (0.51) | METNTRK1DYRK1AWNT1GSK3B | |
| SCHEMBL320855 | 0.87 | MAP4K1 (0.56) | METMAP4K1ALKIRAK4 | |
| SCHEMBL320680 | 0.86 | MET (0.46) | METNTRK1DYRK1AWNT1GSK3B | |
| SCHEMBL12524281 | 0.84 | MAP4K1 (0.47) | METMAP4K1NTRK1DYRK1AWNT1 | |
| SCHEMBL2323319 | 0.83 | MET (0.43) | METMAP4K1NTRK1DYRK1AWNT1 | |
| SCHEMBL320493 | 0.79 | TGFBR1 (0.46) | MAP4K1ALKMAP4K4TGFBR1 | |
| SCHEMBL320734 | 0.79 | MET (0.51) | METNTRK1DYRK1AWNT1GSK3B | |
| SCHEMBL12440269 | 0.78 | MAP4K1 (0.40) | METMAP4K1NTRK1DYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051307-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| EP-2590946-B1 | Bipyridyl derivatives useful for the treatment of kinase-induced diseases | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| EP-2590946-B1 | Bipyridyl derivatives useful for the treatment of kinase-induced diseases | MERCK PATENT GMBH (DE) | 2015-02-18 | — | — | EP | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| US-8846931-B2 | Bipyridyl derivatives | MERCK PATENT GMBH (DE) | 2014-09-30 | — | — | US | disclosed |
| EP-2590946-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | Merck Patent GmbH (DE) | 2013-05-15 | — | — | EP | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2012003912-A1 | BIPYRIDYL DERIVATIVES USEFUL FOR THE TREATMENT OF KINASE - INDUCED DISEASES | MERCK PATENT GMBH (DE) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102608-A1 | BIPYRIDYL DERIVATIVES | TGFBR1, TGFBR2, SMAD2 | MET 341/4885MAP4K1 45/4885NTRK1 946/4885 |
| US-20140336201-A1 | BIPYRIDYL DERIVATIVES | TGFBR1, TGFBR2, SMAD2 | MET 341/4885MAP4K1 45/4885NTRK1 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.